Drug Screening Program

The Drug Screening Program enables researchers and pharmaceutical companies to test promising drugs in chordoma cell and mouse models at a fraction of the time and cost of conducting such studies independently. The program generates preclinical data packages necessary to initiate new clinical trials.

Focus:

• Screening drug candidates in chordoma cell and mouse models
• Testing single agents and drug combinations
• Generating efficacy and safety data
• Supporting the transition from preclinical research to clinical trials

Eligibility:

• Academic researchers
• Pharmaceutical and biotechnology companies
• Collaborations between institutions and industry

How It Works:

• Researchers/companies submit drugs for screening
• Foundation tests in chordoma models
• Results help generate rationale for clinical trials
• Data shared with research partners

Recent Collaborations (as of 2022):

• Sphaera Pharma - testing PI3K/mTOR pathway inhibitor
• Kronos Bio - testing CDK9 inhibitor
• Institute of Cancer Research
• Broad Institute of MIT and Harvard

Advantages:

• Reduced time and cost compared to independent testing
• Access to chordoma-specific expertise and models
• Accelerates development of new treatments

Research Outcomes: Results published at major conferences (AACR) and used to inform clinical trial design

How to Access the Drug Screening Program

1. Contact the Foundation: Interested researchers or companies should contact the Chordoma Foundation to inquire about screening opportunities
2. Submission Process:
   • Present drug candidate(s) and rationale for testing
   • Define testing parameters and endpoints
   • Agree on timeline and data sharing arrangements
3. Program Capabilities:
   • Cell-based screening models
   • Mouse model testing
   • Single agent and combination studies
   • Dose-response and efficacy evaluation
4. Deliverables:
   • Preclinical data packages
   • Results suitable for publication and regulatory submissions
   • Scientific support for clinical trial design

Note: Specific application forms and detailed protocols should be obtained directly from the Foundation.